Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA budget

This article was originally published in The Gray Sheet

Executive Summary

Both the Senate and House Appropriations Committees clear FDA fiscal 2008 funding bills July 19. The Senate bill includes $243.3 million for the device center, about $3 million more than the president requested in February (1"The Gray Sheet" Feb. 12, 2007, p. 3). The House matched the administration's request with a $240.1 million appropriation to CDRH. The Senate committee approved total FDA appropriations of $1.76 billion, slightly more than the House's $1.69 billion. Agency spending will also likely include about $48.5 million in device user fees, though user fee reauthorization legislation is still awaiting the outcome of a House-Senate conference (2"The Gray Sheet" July 16, 2007, p. 4). The House appropriations bill includes language preventing FDA from allowing individuals with financial conflicts to participate in advisory panel meetings. The provision has been included in funding bills for the past two years but has always been removed or weakened before final passage...

You may also be interested in...



FDA User Fee Reauthorization Passes House, Awaits Conference

The House passed broad-based FDA legislation July 11 that includes a package to reauthorize the medical device user fee program

GeneSearch Lymph Node Test Gets Nod For Breast Cancer Assessment

A molecular assay that helps evaluate the extent cancer might have spread from a breast tumor was recommended for approval by FDA's Immunology Devices Panel Nov. 16

Warning Letter Roundup & Recap – 31 March 2020

No device-related warning letters were released by the US FDA the week of 31 March.

UsernamePublicRestriction

Register

MT025048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel